• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sage Therapeutics - Articles and news items


SAGE achieves 77% response rate in Phase 1/2 clinical trial of SAGE-547 in super-refractory status epilepticus

Industry news / 15 May 2015 / Victoria White

SAGE-547 demonstrated robust activity, with a 77% response rate in patients with SRSE, in a successfully completed Phase 1/2 clinical trial…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +